I-MAB ADS news, videos and press releases
For more news please use our advanced search feature.
I-MAB ADS - More news...
I-MAB ADS - More news...
- I-Mab Reports Full Year 2024 Financial Results and Provides Business Update
- I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference
- I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
- I-Mab Announces Accelerated Givastomig Phase 1b Study Progress
- I-Mab to Participate in Leerink Partners Global Healthcare Conference
- I-Mab to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
- I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024
- ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in I-Mab with Losses of $100,000 to Contact the Firm
- INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in I-Mab with Losses of $100,000 to Contact the Firm
- I-Mab Announces Selected Poster Presentation of CD73 Antibody Uliledlimab at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
- I-Mab and ABL Bio Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid Tumors
- I-Mab Announces Upcoming Participation at April Conferences
- I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors
- I-Mab Reports Financial Results for Full Year of 2020 and Provides Business Updates
- I-Mab to Host 2021 R&D Day
- I-Mab Files Prospectus Supplement for Shelf Registration for Hillhouse
- I-Mab To Present Differentiated Mechanism of Action and Preclinical Data for Anti-CD73 Antibody Uliledlimab at 2021 American Association for Cancer Research Annual Meeting
- I-Mab Launches Discovery Initiative to Expand Transformational Immuno-Oncology Pipeline
- I-Mab Filed 2019 Annual Report on Form 20-F
- I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China
- I-Mab Announces Upcoming Participation at May Conferences
- I-Mab Announces Upcoming Participation at April Conferences
- I-Mab Announces IND Clearance from FDA for TJM2 to Treat Cytokine Release Syndrome (CRS) Associated with Severe Coronavirus Disease 19 (COVID-19)
- I-Mab Announces First Patient Dosed in Phase 1/2a Clinical Trial of Anti-CD47 Antibody, TJC4, in China
- I-Mab Announces Financial Results for the Full Year Ended December 31, 2019, and Provides Corporate Update
- I-Mab Submits IND Application to Initiate Study of TJM2 for Treatment of Cytokine Storm Associated with Severe COVID-19 in South Korea
- I-Mab Enters into Strategic Regional Partnership with Kalbe Genexine Biologics for Commercialization Rights of CD73 Antibody, TJD5, for Immuno-Oncology
- I-Mab Expands Global Out-Licensing and Business Development Efforts
- I-Mab Appoints Gigi Feng as Vice President and Global Head of Corporate Communications
- I-Mab Biopharma Announces Development of TJM2 to Treat Cytokine Release Syndrome Associated with Severe and Critically-Ill Patients with Coronavirus Disease (COVID-19)
